average weight loss with tirzepatide Semaglutide vs Tirzepatide: Which GLP-1 Wins for Loss? A new systematic review compared

But state regulators that oversee pharmacies in Louisiana, Mississippi, North Carolina and West Virginia say they are aware that some compounding pharmacists are using a different form of semaglutide that is not approved by the FDA, raising safety concerns

Patients undergoing GLP-1 therapy often report a wide range of benefits that contribute to a greater sense of well-being and a healthier life

Innovation Directions Rather than pursuing oral convenience, leading companies focus on injectable innovation: Extended-release formulations reducing injection frequency (monthly, quarterly) Multi-target mechanisms enhancing efficacy beyond single GLP-1 activation Combination therapies addressing multiple obesity pathways simultaneously Improved delivery devices enhancing patient experience with injections Amgens monthly MariTide exemplifies this approach, achieving 20% weight loss with just 12 annual injections versus 52 for weekly alternatives

2021 Mar 10;14(3):e240140

The STEP 1 trial also showed significant results with blood sugar control, with 84.1% of participants receiving once-weekly semaglutide 2.4 mg having normoglycemia at week 68